IL-23 alpha (170a.a) & IL-12 beta (306a.a) Heterodimer 蛋白, Human (HEK293, His-Avi)

IL-23 alpha and IL-12 beta are the IL-23p19 and IL-12p40 subunits, respectively, composing IL-23 via heterodimerization manner. IL-23 binds to a heterodimeric receptor composed of IL-12RB1 and IL-23R, activates the Jak-Stat signaling cascade, acts on memory CD4(+) T cells preferentially^[1]. IL-23 also involves in activation of several pathways including p38 MAPK or NF-κB and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A^[2]. IL-23 alpha (170a.a) & IL-12 beta (306a.a) Heterodimer Protein, Human is produced in HEK293 cells, with total length of 476 amino acids and a C-Terminal His- and Avi-tag.

IL-23 α 和 IL-12 β 分别也称为 IL23p19 和 IL12p40，以异二聚化方式组成 IL-23，发挥促炎作用并促进血管生成^[1][5]。
IL-23与IL-12 p35/p40、IL-27 EBI3/p28和IL-35 EBI3/p35同属于IL-12细胞因子家族，由多种免疫产生。^[3]。
IL-23 优先在记忆 CD4(+) T 细胞上表达，并激活 Jak -Stat信号级联。IL-23 会导致 IL-23 受体磷酸化，并形成对接位点来触发 STAT3 和 STAT4 的磷酸化信号^[1]。
IL-23 是维持 Th17 细胞活化的关键因素，通过结合 IL-23 受体产生 Th17 细胞因子，例如 IL17 A、IL-17 F 和 IL-22^[2]，从而产生细胞因子。
IL-23 还对自然杀伤细胞起作用，导致干扰素-γ分泌增加，增强抗体依赖性细胞毒性^[4]。
人IL-23α蛋白氨基酸序列与食蟹猴具有高度相似性（97.88%） ），与小鼠（74.60%）或大鼠（79.37%）有很大差异，而人的IL-12β蛋白序列与小鼠（69.04%）和大鼠（69.04%）有很大差异。
IL -23 促进许多其他先前与 IL-12 相关的免疫病理学模型中炎症的发展，包括关节炎、肠道炎症和牛皮癣模型^[6][7][8]。

Human

HEK293

C-Avi;C-His

Q9NPF7 (R20-P189)&P29460 (I23-S328)

51561  [NCBI]&3593  [NCBI]

Approximately 20 kDa

Greater than 95% as determined by Tris-Bis PAGE

<1 EU/μg, determined by LAL method.

• [1]. Oppmann B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000 Nov;13(5):715-25.  [Content Brief]

  [2]. Parham C, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002 Jun 1;168(11):5699-708.  [Content Brief]

  [3]. Neurath MF. IL-23 in inflammatory bowel diseases and colon cancer. Cytokine Growth Factor Rev. 2019 Feb;45:1-8.  [Content Brief]

  [4]. Teng MW, et al. IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases. Nat Med. 2015 Jul;21(7):719-29.  [Content Brief]

  [5]. Li Y, et al. Regulation of Memory T Cells by Interleukin-23. Int Arch Allergy Immunol. 2016;169(3):157-62.  [Content Brief]

  [6]. Langowski JL, et al. IL-23 promotes tumour incidence and growth. Nature. 2006 Jul 27;442(7101):461-5.  [Content Brief]

  [7]. Murphy CA, et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med. 2003 Dec 15;198(12):1951-7.  [Content Brief]

  [8]. Yen D, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest. 2006 May;116(5):1310-6.  [Content Brief]

  [9]. Chan JR, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006 Nov 27;203(12):2577-87.  [Content Brief]

  [10]. Yago T, et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Res Ther. 2007;9(5):R96.  [Content Brief]